Built-in stabilization platform and integrated extension set
,Designed to reduce manipulation and movement at the site. Have been shown to reduce dislodgment by 84% and mechanical phlebitis.1,2
98% reduced blood exposure during insertion due to the pre-assembled system.2
,Dwells longer
,Median dwell time for BD NexivaTM Closed IV Catheters versus the open-system catheters studied in a randomized trial of PIVCs in place for more than 24 hours.1
,BD Vialon™ catheter material
,Proprietary BD Vialon™ Catheter Material softens, enabling longer dwell time and reducing the chance of phlebitis up to 69%.3
,BD Instaflash™ needle technology
,Provides quick blood visualization that may help improve insertion success and therefore reduce insertion attempts.
,Canadian Vascular Access & Infusion Therapy Guidelines
,Recommend using extension set (integrated preferred) on PVAD (to reduce manipulations and avoid dislodgement), and using suture-less securement (including engineered securement devices) to limit movement of VAD. Method of securement can include an integrated stabilization feature on PVAD.
Recommend not removing VAD based solely on length of dwell time, as optimum dwell time is unknown.6
,Centers for Disease Control and Prevention
,Catheter stabilization is recognized as an intervention to decrease the risk for phlebitis, catheter migration and dislodgement and may be advantageous in preventing catheter-related bloodstream infections (CRBSIs).3
,Infusion Therapy Standards of Practice
,Recommend limiting the use of add-on devices to reduce the potential for contamination, additional manipulation, and disconnection.5
,Increased clinician safety
,98% reduced blood exposure during insertion due to the BD Nexiva IV catheter preassembled system.2*
,Increased catheter stabilization
,Clinically demonstrated to reduce accidental dislodgement,2‡ meeting Infusion Nursing Society standards4 and CDC guidelines5 for catheter stabilization.
,Reduced rate of complications
,In a clinical study, results demonstrated a significant reduction in the rate of phlebitis (grade 2 or higher), PIVC-related complications, and infiltration in the closed system versus the open system group.1